MedTrace Logo

Cardiovascular Effects of Apelin In Healthy Volunteers

NCT02259686 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2015-06-01

No results posted yet for this study

Summary

Apelin is an endogenous peptide with physiological actions in the cardiovascular system. Apelin can modulate vasomotor tone and is a potent endogenous inotrope. In a series of clinical studies, we have shown that apelin causes peripheral and coronary vasodilatation and increased cardiac contractility. We wish to study and compare the cardiovascular effects of subcutaneous versus intravenous apelin. We specifically wish to determine how different methods of apelin administration affect cardiac output and peripheral vascular resistance in healthy volunteers

Conditions

  • Healthy

Interventions

DRUG

Apelin 1mg subcutaneous

single subcutaneous injection of Apelin 1mg subcutaneous

DRUG

Apelin 1mg intravenous

15 minute intravenous bolus of Apelin 1mg intravenous

DRUG

Apelin 5mg subcutaneous

single subcutaneous injection of Apelin 5mg subcutaneous

DRUG

Apelin 5mg intravenous

15 minute intravenous infusion of Apelin 5mg intravenous

DRUG

Apelin 10 mg subcutaneous

24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous

Sponsors & Collaborators

  • NHS Lothian

    collaborator OTHER_GOV

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • David Newby · British Heart Foundation

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02259686 on ClinicalTrials.gov